AllergyTalk Episode 55 - What Are the Best Criteria to Identify MCAS?
Description
Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®.
Articles Reviewed:
- Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections
- A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study
- Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:
Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose
Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose
Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
United States
